XTX301 Phase 1/2 Trial Initiated for Advanced Solid Tumors
Xilio Development, Inc. has initiated a first-in-human Phase 1/2 trial to evaluate XTX301 in patients with advanced solid tumors.
Asset / Drug
Drug and asset intelligence for XTX301 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.